Brought to you by 
Biocartis SA gets €30mm via Series B
Apr 2010
Executive Summary
Molecular diagnostics company Biocartis SA raised €30mm ($40.2mm) in its Series B financing to first-time backers Debiopharm Group and Johnson & Johnson Development Corp., which were joined by returning shareholders Aescap, Biovest, Advent Venture Partners, Biocartis employees, and Benaruca (the family investment firm of the company's co-founder and CEO Rudi Pauwels). Funding will support continued late-stage development of its diagnostics platform. A member of Debiopharm will join the Biocartis board.
Deal Industry
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biocartis SA gets €30mm via Series B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice